These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2747246)

  • 1. Clinical value of in vitro drug sensitivity testing based on short-term effects on DNA and RNA metabolism in ovarian cancer.
    Khoo SK; Hurst T; Webb MJ; Dickie G; Kearsley J; Parsons PG; Mackay EV
    J Surg Oncol; 1989 Jul; 41(3):201-5. PubMed ID: 2747246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosensitivity testing of ovarian cancer: results of a rapid in vitro biochemical assay.
    Khoo SK; Hurst T; Webb MJ
    Aust N Z J Obstet Gynaecol; 1985 Aug; 25(3):215-20. PubMed ID: 3866561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect].
    Takamizawa H; Sekiya S; Iwasawa H; Ishige H; Tokita H; Tanaka N
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2293-7. PubMed ID: 2416274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin chemotherapy of ovarian cancer: is short-term in vitro chemosensitivity predictive of long-term patient survival?
    Khoo SK; Hurst T; Webb MJ; Dickie G; Kearsley J; Parsons PG; Mackay EV
    Aust N Z J Obstet Gynaecol; 1988 Nov; 28(4):313-7. PubMed ID: 3250450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractional incorporation of radionucleotides, a marker of in vitro tumor cell chemosensitivity in colorectal cancer.
    Franchi F; Seminara P; Giannarelli D; Konovalova N
    Oncology; 1991; 48(6):510-6. PubMed ID: 1749592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
    Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
    Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term in vitro chemosensitivity testing of tumours of the ovary, cervix and uterus. Measurement of DNA metabolism by 3H thymidine incorporation.
    Khoo SK; Hurst T; Webb MJ; Mackay EV
    Aust N Z J Obstet Gynaecol; 1986 Nov; 26(4):288-94. PubMed ID: 3469997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application.
    Saito H; Ohtsubo T; Fujieda S; Tanigawa N
    Eur Arch Otorhinolaryngol; 1992; 249(7):400-3. PubMed ID: 1283305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
    Untch M; Sevin BU; Perras JP; Angioli R; Baibl A; Nguyen HN; Hightower RD; Averette HE
    Gynecol Oncol; 1992 Nov; 47(2):172-8. PubMed ID: 1468695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB; Zhang Y; Frenkel GD
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing.
    Gerçel-Taylor C; Ackermann MA; Taylor DD
    Anticancer Res; 2001; 21(4A):2761-8. PubMed ID: 11724352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
    Tamura M; Takakuwa K; Tanaka K
    Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro sensitivity of ovarian cancer as determined by a short-term biochemical assay: comparison between primary and metastatic sites in the same patient.
    Khoo SK; Hurst T; Lark J; Webb MJ; Parsons P; Mackay EV
    Gynecol Oncol; 1989 Feb; 32(2):151-5. PubMed ID: 2910775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
    Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
    Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT; Sevin BU
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
    Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
    Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
    Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
    Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
    Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.